Roche announced an expanded partnership with Nvidia to bolster its AI 'factory' for drug and diagnostic development, aiming to accelerate model training, molecular design, and diagnostic pipelines using Nvidia’s compute and accelerated software stack. The move follows other big pharma investments in Nvidia supercomputing and positions Roche to scale AI across discovery, translational research, and diagnostics. Roche framed the deal as a step to shorten development timelines and enhance in‑house AI capabilities while integrating high‑performance compute into regulated workflows for development and validation. Source: Roche corporate announcement and industry reporting.